Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TG6050 |
| Synonyms | |
| Therapy Description |
TG6050 is an oncolytic vaccinia virus engineered to express IL-12 and an anti-CTLA4 antibody, which potentially leads to enhanced antitumor immune response and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 694). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TG6050 | TG-6050|TG 6050 | TG6050 is an oncolytic vaccinia virus engineered to express IL-12 and an anti-CTLA4 antibody, which potentially leads to enhanced antitumor immune response and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 694). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05788926 | Phase I | TG6050 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | Terminated | FRA | 0 |